Interobserver Variability of Transrectal Ultrasound for Prostate Volume Measurement According to Volume and Observer Experience

2009 ◽  
Vol 192 (2) ◽  
pp. 444-449 ◽  
Author(s):  
Young Jun Choi ◽  
Jeong Kon Kim ◽  
Hyun Jin Kim ◽  
Kyoung-Sik Cho
Keyword(s):  
Interobserver Variability ◽  
Prostate Volume ◽  
Transrectal Ultrasound ◽  
Volume Measurement ◽  
Observer Experience

Prostate volume measurement by transrectal ultrasound and computed tomography before and after permanent prostate brachytherapy

2004 ◽  
Vol 60 (3) ◽  
pp. 767-776 ◽  
Author(s):  
Matthew C. Solhjem ◽  
Brian J. Davis ◽  
Thomas M. Pisansky ◽  
Torrence M. Wilson ◽  
Lance A. Mynderse ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Prostate Volume ◽  
Transrectal Ultrasound ◽  
Volume Measurement ◽  
Prostate Brachytherapy ◽  
Before And After

The Comparison of Imaging and Clinical Methods to Estimate Prostate Volume: A Single-Centre Retrospective Study

2021 ◽  
pp. 1-7
Author(s):  
Matteo Massanova ◽  
Sophie Robertson ◽  
Biagio Barone ◽  
Lorenzo Dutto ◽  
Vincenzo Francesco Caputo ◽  
...  
Keyword(s):  
Radical Prostatectomy ◽  
Prostate Volume ◽  
Transrectal Ultrasound ◽  
Digital Rectal Examination ◽  
Benign Prostatic Hypertrophy ◽  
Volume Measurement ◽  
Surgical Specimen ◽  
Significant Difference ◽  
Ellipsoid Volume

<b><i>Background:</i></b> Prostate volume (PV) is a useful tool in risk stratification, diagnosis, and follow-up of numerous prostatic diseases including prostate cancer and benign prostatic hypertrophy. There is currently no accepted ideal PV measurement method. <b><i>Objective:</i></b> This study compares multiple means of PV estimation, including digital rectal examination (DRE), transrectal ultrasound (TRUS), and magnetic resonance imaging (MRI), and radical prostatectomy specimens to determine the best volume measurement style. <b><i>Methods:</i></b> A retrospective, observational, single-site study with patients identified using an institutional database was performed. A total of 197 patients who underwent robot-assisted radical prostatectomy were considered. Data collected included age, serum PSA at the time of the prostate biopsy, clinical T stage, Gleason score, and PVs for each of the following methods: DRE, TRUS, MRI, and surgical specimen weight (SPW) and volume. <b><i>Results:</i></b> A paired <i>t</i> test was performed, which reported a statistically significant difference between PV measures (DRE, TRUS, MRI ellipsoid, MRI bullet, SP ellipsoid, and SP bullet) and the actual prostate weight. Lowest differences were reported for SP ellipsoid volume (<i>M</i> = −2.37; standard deviation [SD] = 10.227; <i>t</i>[167] = −3.011; and <i>p</i> = 0.003), MRI ellipsoid volume (<i>M</i> = −4.318; SD = 9.53; <i>t</i>[167] = −5.87; and <i>p</i> = 0.000), and MRI bullet volume (<i>M</i> = 5.31; SD = 10.77; <i>t</i>[167] = 6.387; and <i>p</i> = 0.000). <b><i>Conclusion:</i></b> The PV obtained by MRI has proven to correlate with the PV obtained via auto-segmentation software as well as actual SPW, while also being more cost-effective and time-efficient. Therefore, demonstrating that MRI estimated the PV is an adequate method for use in clinical practice for therapeutic planning and patient follow-up.

scholarly journals Predictors of Gleason score upgrading in patients with prostate biopsy Gleason score ≤6

2014 ◽  
Vol 8 (5-6) ◽  
pp. 342 ◽  
Author(s):  
Hasmet Sarici ◽  
Onur Telli ◽  
Orhan Yigitbasi ◽  
Musa Ekici ◽  
Berat Cem Ozgur ◽  
...  
Keyword(s):  
Gleason Score ◽  
Prostate Biopsy ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Transrectal Ultrasound ◽  
Radical Retropubic Prostatectomy ◽  
Small Sample ◽  
Ultrasound Guided ◽  
Increased Risk ◽  
Biopsy Gleason Score

Introduction: The discrepancy between prostate biopsy and prostatectomy Gleason scores is common. We investigate the predictive value of prostate biopsy features for predicting Gleason score (GS) upgrading in patients with biopsy Gleason scores ≤6 who underwent radical retropubic prostatectomy (RRP). Our aim was to determine predictors of GS upgrading and to offer guidance to clinicians in determining the therapeutic option.Methods: We performed a retrospective study of patients who underwent RRP for clinically localized prostate cancer at 2 major centres between January 2007 and March 2013. All patients with either abnormal digital examination or elevated prostate-specific antigen at screening underwent transrectal ultrasound-guided prostate biopsy. Variables were evaluated among the patients with and without GS upgrading. Our study limitations include its retrospective design, the fact that all subjects were Turkish and the fact that we had a small sample size.Results: In total, 321 men had GS ≤6 on prostate biopsy. Of these, 190 (59.2%) had GS ≤6 concordance and 131 (40.8%) had GS upgrading from ≤6 on biopsy to 7 or higher at the time of the prostatectomy. Independent predictors of pathological upgrading were prostate volume <40 cc (p < 0.001), maximum percent of cancer in any core (p = 0.011), and >1 core positive for cancer (p < 0.001).Conclusions: When obtaining an extended-core biopsy scheme, patients with small prostates (≤40 cc), greater than 1 core positive for cancer, and an increased burden of cancer are associated with increased risk of GS upgrading. Patients with GS ≤6 on biopsy with these pathological parameters should be carefully counselled on treatment decisions.

Body Mass Index, Prostate Weight and Transrectal Ultrasound Prostate Volume Accuracy

2007 ◽  
Vol 178 (3) ◽  
pp. 990-995 ◽  
Author(s):  
Kamran P. Sajadi ◽  
Martha K. Terris ◽  
Robert J. Hamilton ◽  
Jennifer Cullen ◽  
Christopher L. Amling ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Body Mass ◽  
Prostate Volume ◽  
Transrectal Ultrasound ◽  
Prostate Weight

Effect of alpha-blocker use on morbidity and lower urinary tract symptoms in patients undergoing transrectal ultrasound-guided prostate biopsy

2021 ◽  
pp. 039156032110383
Author(s):  
Remzi Salar ◽  
Güven Erbay
Keyword(s):  
Prostate Biopsy ◽  
Voiding Dysfunction ◽  
Prostate Volume ◽  
Transrectal Ultrasound ◽  
Urine Volume ◽  
Maximum Flow ◽  
Control Group ◽  
Alpha Blocker ◽  
Urinary Tract Symptoms ◽  
Significant Difference

Objective: To evaluate voiding dysfunction and morbidity after transrectal ultrasound (TRUS)-guided prostate biopsy and to investigate whether pre-intervention alpha-blocker treatment had any effect on morbidity and voiding dysfunction. Material and methods: The study included 197 consecutive patients who underwent TRUS-guided prostate biopsy between January 2014 and January 2018. The patients were divided into two groups, those receiving alpha-blocker (silodosin) and those not receiving alpha-blocker treatment before the procedure (controls). All patients were evaluated before and one week after the procedure with the International Prostate Symptom Score (IPSS), measurements of maximum flow rate ( Qmax), post-void residual urine volume (PVR) and prostate volume, and procedure-related complications were also recorded. All analyzed parameters were compared by within-group and between-group evaluations. Results: There was no significant difference between the two groups in terms of IPSS, Qmax and prostate volume values before biopsy. In the follow-up evaluation performed on the seventh day after biopsy, IPSS, PVR and prostate volume were found to be increased, whereas Qmax was decreased in the control group ( p < 0.05). In the silodosin group, an increase in prostate volume was observed, but there were no significant changes in IPSS, Qmax and PVR values. Acute urinary retention (AUR) after the biopsy procedure developed in two patients (2%) in the silodosin group, and in nine patients (9.1%) in the control group ( p = 0.02). No significant difference was found between the two groups in terms of biopsy-related complications, except for AUR. Conclusion: We believe that alpha-blocker treatment initiated before biopsy may be advantageous in preventing voiding dysfunction that may develop after the procedure.

Can the PSAD (Prostate Specific Antigen Density) be Useful in the Diagnosis of Prostate Carcinoma?

1993 ◽  
Vol 60 (4) ◽  
pp. 307-308
Author(s):  
E. Gastaldi ◽  
S. Benvenuti ◽  
B. Mennini ◽  
M. Iacoviello ◽  
M. Caviglione ◽  
...  
Keyword(s):  
Prostate Specific Antigen ◽  
Sensitivity And Specificity ◽  
Prostate Carcinoma ◽  
Prostate Volume ◽  
Specific Antigen ◽  
Transrectal Ultrasound ◽  
Prostate Specific Antigen Density

PSA (prostate specific antigen) has not demonstrated sufficient sensitivity and specificity to be useful in the evaluation of prostate carcinoma. To enhance the accuracy of serum PSA the Authors have used a quotient of serum PSA (ng/ml) and prostate volume (calculated by transrectal ultrasound) which is named PSAD (prostate specific antigen density).

scholarly journals Prostate Volume Measurement by TRUS Using Heights Obtained by Transaxial and Midsagittal Scanning: Comparison with Specimen Volume Following Radical Prostatectomy

2000 ◽  
Vol 1 (2) ◽  
pp. 110 ◽  
Author(s):  
Sung Bin Park ◽  
Jae Kyun Kim ◽  
Sung Hoon Choi ◽  
Han Na Noh ◽  
Eun Kyung Ji ◽  
...  
Keyword(s):  
Radical Prostatectomy ◽  
Prostate Volume ◽  
Volume Measurement ◽  
Specimen Volume
Sign in / Sign up

Export Citation Format

Share Document